SCHEMBL22740482

SCHEMBL22740482

Cc1cc(C)cc(N(c2cc(C)cc(C)c2)c2ccc3cc4c(cc3c2)oc2c3oc5cc6cc(N(c7cc(C)cc(C)c7)c7cc(C)cc(C)c7)ccc6cc5c3c(-c3ccccc3)c(-c3ccccc3)c42)c1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ERAP1 Q9NZ08 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ DYRK1A Q13627 1/20 0.32
▸ KMT2A Q03164 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ BLM P54132 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.30
▸ ESR1 P03372 1/20 0.30
▸ ESR2 Q92731 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ STAT1 P42224 1/20 0.30
▸ RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22743063 0.98 ERAP1 (0.32) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22740813 0.94 ERAP1 (0.31) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22742917 0.94 ERAP1 (0.32) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22740589 0.92 ERAP1 (0.32) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22740384 0.92 — —
SCHEMBL22741145 0.92 ERAP1 (0.33) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22740598 0.91 ERAP1 (0.32) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22740385 0.90 ERAP1 (0.34) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22740595 0.89 ESR1 (0.33) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL22740386 0.88 DYRK1A (0.34) ERAP1ALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200377513-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2020-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377513-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE PIEZO1, TMEM109, LEF1 ERAP1 4543/4885ALDH1A1 216/4885CYP1A2 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback